Pharma Mar SA (ES:PHM) has released an update.
Pharma Mar and Jazz Pharmaceuticals have announced promising phase III trial results for their drug combination of Zepzelca® and atezolizumab, which significantly improves survival rates for patients with advanced stage small cell lung cancer. The companies plan to seek regulatory approval in the U.S. and Europe by 2025, highlighting a potential new treatment option for this aggressive cancer. These findings could offer a much-needed advancement in extending patient survival.
For further insights into ES:PHM stock, check out TipRanks’ Stock Analysis page.
